CODON CAPITAL
  • Home
  • Investment Focus
  • Team
Picture

The Codon Capital Approach

It is easy to predict the future of biotechnology, but it is difficult to know who will invent it, what business success it will fuel. How long will it take?  What are the key obstacles that stopped others before, where we see a path (or better: multiple paths) forward to a new innovative technology. Codon Capital knows how to recognize the what ifs with a technical path that enable breakthrough products.
Codon Capital News: Mitchell Mutz, PhD joins as Partner

'Everything is the technology of the future, until it works.'
                          
                      -Karl D. Handelsman, Founder & Managing Partner, Codon Capital


Picture

Therapeutics

Picture
Investment FocusInnovation Meeting Unmet Medical Needs
Picture

Synthetic Biology

Picture
Investment FocusBetter, Faster, Cheaper Biology

START-UP ECOSYSTEM


We're a partner to the great teams that come together to solve technical challenges and build important businesses.
YEARS COMBINED BIOTECH
VENTURE EXPERIENCE

      
IPOs
COMPANIES EXITED FROM SEED or SERIES A
IN LESS THAN 18 MONTHS

27 Investments

Amplyx Pharmaceuticals • Antheia • Araxes Pharma • Arcus Biosciences • Avidity Biosciences • Bolt Threads • Caribou Biosciences • Clear Labs • eGenesis • EpiBiome • Flexus Biosciences •  Glycostasis • Good Therapeutics • Jasper Therapeutics • Kumquat Biosciences • Kura Oncology • Oric Pharmaceuticals •  Pivot Bio • RAPT Therapeutics • Shattuck Labs • Vaxart • ViewPoint Therapeutics • Zephyrus Biosciences • Zymergen

About Codon

Codon Capital is a San Francisco-based biotech venture capital company, specializing in therapeutics and synthetic biology. Our investment approach is to fund startup teams that can execute on difficult technical, definable achievements that enable breakthrough biotech products. We’re investing in solutions to the most critical problems of human health and sustainability, and in teams who can make the "impossible" possible.

Our early stage investments back teams to build enduring quality solutions, which sometimes are snapped up via acquisitions, but also have the option to raise additional equity at attractive valuations to seek even more value.
Picture

Codon Capital  |  San Francisco, CA

© 2019-2020 Content: Codon Capital.  Artwork: Creative Market.                                                       Codon Capital | BioTech Venture Investment | San Francisco
  • Home
  • Investment Focus
  • Team